INAVO120 - Clinical trial • Breast Cancer Foundation NZ

We're here to help during Covid-19. Find out more here. 

INAVO120

Advanced Breast Cancer clinical trials for ER+

Recruiting
Updated: July 13, 2021

This phase 3 study will evaluate the efficacy and safety of GDC-0077 in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, ER+, HER2-negative locally advanced or metastatic breast cancer.

Key inclusion criteria:

  • Confirmed diagnosis of HR+/HER2- breast cancer
  • Metastatic or locally advanced disease not amenable to curative therapy
  • Progression of disease during adjuvant endocrine treatment or within 12 months of completing adjuvant endocrine therapy with an aromatase inhibitor or tamoxifen
  • Confirmation of biomarker eligibility (detection of specified mutation(s) of PIK3CA via specified test)
  • Life expectancy of > 6 months
  • Adequate hematologic and organ function within 14 days prior to initiation of study treatment

Full trial information

New Zealand

Auckland City Hospital
Christchurch Hospital
Palmerston North Hospital
Waikato Hospital

Australia

Mater Adult Hospital, Brisbane
Princess Alexandra Hospital, Brisbane
Cairns Base Hospital, Cairns (not yet recruiting)
Austin Health, Melbourne
Peninsula and South Eastern Haematology and Oncology Group, Melbourne
Peter MacCallum Cancer Centre, Melbourne
Western Health, Melbourne
Townsville Hospital, Townsville
Southern Medical Day Centre, Wollongong

If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.

Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz

Similar clinical trials

For Advanced Breast Cancer

Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz

Find clinical trials

Interested in a clinical trial?

Subscribe for updates & stay in the loop with new studies.